Bayer board of directors receives bonus despite high glyphosate costs – shareholders express clear criticism

Dusseldorf The remuneration of Bayer’s board of management has met with ongoing criticism from investors and proxy advisors. Reason: In 2022, Bayer also had to deal with billions in costs to eliminate glyphosate lawsuits – without affecting short-term bonus payments to management. Several funds had already criticized this rule last year.

The group is therefore threatened with another defeat in relation to the remuneration of the board of directors at the general meeting next Friday. As early as 2022, around 75 percent of shareholders had voted against the remuneration report presented. Bayer defends the regulation as “customary” and has announced an “action plan” after last year’s defeat. For critics, however, this does not go far enough.